Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Pablo Morentin-Gutierrez"'
Autor:
Thomas G. Hayhow, Beth Williamson, Mandy Lawson, Natalie Cureton, Erin L. Braybrooke, Andrew Campbell, Rodrigo J. Carbajo, Azadeh Cheraghchi-Bashi, Elisabetta Chiarparin, Coura R. Diène, Charlene Fallan, David I. Fisher, Frederick W. Goldberg, Lorna Hopcroft, Philip Hopcroft, Anne Jackson, Jason G. Kettle, Teresa Klinowska, Ulrike Künzel, Gillian Lamont, Hilary J. Lewis, Gareth Maglennon, Scott Martin, Pablo Morentin Gutierrez, Christopher J. Morrow, Myria Nikolaou, J. Willem M. Nissink, Patrick O’Shea, Radoslaw Polanski, Markus Schade, James S. Scott, Aaron Smith, Judith Weber, Joanne Wilson, Bin Yang, Claire Crafter
Publikováno v:
Communications Biology, Vol 7, Iss 1, Pp 1-17 (2024)
Abstract Targeting the estrogen receptor alpha (ERα) pathway is validated in the clinic as an effective means to treat ER+ breast cancers. Here we present the development of a VHL-targeting and orally bioavailable proteolysis-targeting chimera (PROT
Externí odkaz:
https://doaj.org/article/ec006f9560824ea494be6041bb1eeb60
Autor:
Larissa Carnevalli, Susana Ros, Jelena Urosevic, Natalie Cureton, Sophie Darcy, Mandy Lawson, Stuart Williamson, Pablo Morentin Gutierrez, Azadeh Bashi, Jennifer Moss, Christopher Morrow, Barry Simon, Teresa Klinowska
Publikováno v:
Cancer Research. 83:PD10-04
Next-generation oral selective estrogen receptor degraders (ngSERDs) are aiming to become the backbone endocrine therapy (ET) for patients with estrogen receptor positive (ER+) breast cancer (BC) by achieving greater ER signaling blockade than curren
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f8282daf36c5d38b3097f50ee2a0db98
https://doi.org/10.1158/1538-7445.sabcs22-pd10-04
https://doi.org/10.1158/1538-7445.sabcs22-pd10-04
Autor:
Larissa S. Carnevalli, Charles Sinclair, Molly A. Taylor, Pablo Morentin Gutierrez, Sophie Langdon, Anna M. L. Coenen-Stass, Lorraine Mooney, Adina Hughes, Laura Jarvis, Anna Staniszewska, Claire Crafter, Ben Sidders, Elizabeth Hardaker, Kevin Hudson, Simon T. Barry
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-14 (2018)
Abstract PI3K inhibitors with differential selectivity to distinct PI3K isoforms have been tested extensively in clinical trials, largely to target tumor epithelial cells. PI3K signaling also regulates the immune system and inhibition of PI3Kδ modul
Externí odkaz:
https://doaj.org/article/d8dfe19702e54dfe8e8186c3eeb57177
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics.
The value of an integrated mathematical modelling approach for protein degraders which combines the benefits of traditional turnover models and fully mechanistic models is presented. Firstly, we show how exact solutions of the mechanistic models of m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0827f90435b74d1e9265e4e2097e5961
https://doi.org/10.1007/s10928-023-09857-9
https://doi.org/10.1007/s10928-023-09857-9
Autor:
Stephen Green, Francisco Cruzalegui, Lara Ward, Sabina C. Cosulich, Marie Cumberbatch, Alys Jones, Rebecca Ellston, Lyndsey Hanson, Phillippa Dudley, Oona Delpuech, Alvaro Avivar-Valderas, Pablo Morentin Gutierrez, Myria Nikolaou, Urszula M. Polanska, Robert McEwen, Cath Trigwell, Urs J. Hancox, Kevin Hudson
The PIK3CA gene, encoding the p110α catalytic unit of PI3Kα, is one of the most frequently mutated oncogenes in human cancer. Hence, PI3Kα is a target subject to intensive efforts in identifying inhibitors and evaluating their therapeutic potentia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::282c99e85c18ba37f3ab7df829957e4b
https://doi.org/10.1158/1535-7163.c.6538756
https://doi.org/10.1158/1535-7163.c.6538756
Autor:
Stephen Green, Francisco Cruzalegui, Lara Ward, Sabina C. Cosulich, Marie Cumberbatch, Alys Jones, Rebecca Ellston, Lyndsey Hanson, Phillippa Dudley, Oona Delpuech, Alvaro Avivar-Valderas, Pablo Morentin Gutierrez, Myria Nikolaou, Urszula M. Polanska, Robert McEwen, Cath Trigwell, Urs J. Hancox, Kevin Hudson
Timecourse of PI3K pathway inhibition in MCF7 cells illustrating pathway reactivation over time.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00456e2abd72de83084efc8b4c7deb65
https://doi.org/10.1158/1535-7163.22507708
https://doi.org/10.1158/1535-7163.22507708
Autor:
Stephen Green, Francisco Cruzalegui, Lara Ward, Sabina C. Cosulich, Marie Cumberbatch, Alys Jones, Rebecca Ellston, Lyndsey Hanson, Phillippa Dudley, Oona Delpuech, Alvaro Avivar-Valderas, Pablo Morentin Gutierrez, Myria Nikolaou, Urszula M. Polanska, Robert McEwen, Cath Trigwell, Urs J. Hancox, Kevin Hudson
Tumor cell line panel composition and growth inhibition sensitivity (GI50) to AZD8835.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d4782fd316b02ec8951d691e4f7122f
https://doi.org/10.1158/1535-7163.22507675.v1
https://doi.org/10.1158/1535-7163.22507675.v1
Autor:
Simon T. Barry, Stephen E. Fawell, Teresa Klinowska, Susan E. Critchlow, Cristina Gardelli, Pablo Morentin Gutierrez, Michele Moschetta, Maneesh Singh, Danielle Carroll, Neha Wali, Antonio Ramos-Montoya, Yanjun Wang, Theresa A. Proia, Sigourney Bell, Adina M. Hughes, Anna M.L. Coenen-Stass, Matthew King, Molly A. Taylor, Larissa S. Carnevalli
Suppressive myeloid cells mediate resistance to immune checkpoint blockade. PI3Kγ inhibition can target suppressive macrophages, and enhance efficacy of immune checkpoint inhibitors. However, how PI3Kγ inhibitors function in different tumor microen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d5db27890affeab7375808ed1468dea
https://doi.org/10.1158/1535-7163.c.6543334
https://doi.org/10.1158/1535-7163.c.6543334
Autor:
Simon T. Barry, Stephen E. Fawell, Teresa Klinowska, Susan E. Critchlow, Cristina Gardelli, Pablo Morentin Gutierrez, Michele Moschetta, Maneesh Singh, Danielle Carroll, Neha Wali, Antonio Ramos-Montoya, Yanjun Wang, Theresa A. Proia, Sigourney Bell, Adina M. Hughes, Anna M.L. Coenen-Stass, Matthew King, Molly A. Taylor, Larissa S. Carnevalli
Supplementary Figure 1. Pharmacokinetic (PK) properties of AZD3458 in mouse. Supplementary Figure 2. In vivo pharmacodynamic properties of AZD3458 in mouse neutrophils. Supp Fig 3. PI3K-�/mTOR pathway regulates expression of IL-10/IL-12 via LPS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::948d7693e031fd14364c926a362ec350
https://doi.org/10.1158/1535-7163.22522333.v1
https://doi.org/10.1158/1535-7163.22522333.v1
Autor:
Simon T. Barry, Stephen E. Fawell, Teresa Klinowska, Susan E. Critchlow, Cristina Gardelli, Pablo Morentin Gutierrez, Michele Moschetta, Maneesh Singh, Danielle Carroll, Neha Wali, Antonio Ramos-Montoya, Yanjun Wang, Theresa A. Proia, Sigourney Bell, Adina M. Hughes, Anna M.L. Coenen-Stass, Matthew King, Molly A. Taylor, Larissa S. Carnevalli
Supplementary Materials and Methods. Suplementary Table 1. Tumor Immuno-phenotyping. Suplementary Table 2. Flow cytometry panels.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05e4df3e39a49aa5d8ff897330704dc2
https://doi.org/10.1158/1535-7163.22522330
https://doi.org/10.1158/1535-7163.22522330